A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
Phase: PHASE3
Conditions: Major Depressive Disorder
Sponsor: Relmada Therapeutics, Inc.

CLINICAL STUDY PROTOCOL 
Protocol Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study to Assess the Efficacy and Safety of REL-1017 for Treatment 
of Major Depressive Disorder 
(The RELIANCE-I Study) 
Protocol Number: REL-1017-301 
NCT Number: 
NCT04688164 
Name of Investigational Product: 
REL-1017 
Phase of Development: 
3 
Indication: 
Major Depressive Disorder 
Sponsor: 
Relmada Therapeutics Inc. 
Document Date: 
December 01 2022 
Certain information within this protocol has been redacted to protect either personally 
identifiable information or company confidential information. 
This may include, but is not limited to, redaction of the following: 
•
Names, addresses, and other personally identifiable information
•
Proprietary information, such as scales or coding systems, which are considered 
confidential information.
•
Other information as needed to protect the trade secret and/or confidential information of 
Relmada Therapeutics

INVESTIGATOR SIGNATURE PAGE 
Protocol Title: 
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 
Study to Assess the Efficacy and Safety of REL-1017 for Treatment of 
Major Depressive Disorder (The RELIANCE-I Study) 
Protocol Number: 
REL-1017-301 
Confidentiality and Current Good Clinical Practice (GCP)/E6(R2): 
I agree, as an Investigator conducting this study: 
• 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
<Name> 
<Title> 
Investigator Signature 
Date (DD-Mmm-YYYY) 
Institution